Cognex Corporation (NASDAQ:CGNX) [Trend Analysis] knocking active thrust in leading trading session, shares an advance of 8.50% to 76.44 with around 2.03 Million shares have changed hands in this session. Cognex Corp. (CGNX) declared that its Q4 net income from continuing operations of $38.25 million or $0.43 per share compared to $18.85 million or $0.22 per share, previous year. On average, nine analysts polled by Thomson Reuters expected the company to report profit per share of $0.29 for the quarter. Analysts’ estimates typically exclude special items.
Fourth-quarter revenue surged to $129.32 million from $97.77 million, a year ago. Analysts expected revenue of $116.93 million for the quarter. The company said the growth year-on-year came from a variety of industries, including automotive, consumer electronics and logistics. Gross margin was 79% compared to 76%, prior year.
Gross margin surged year-on-year due to cost improvements and manufacturing efficiencies.For first-quarter, the company expects revenue to be between $122 million and $125 million, which represents growth of 27% to 30% year-on-year. Gross margin is expected to be in the mid-to-high 70% range. The stock is going forward its fifty-two week low with 122.65% and lagging behind from its 52-week high price with 8.16%.
Similar, the positive performance for the quarter recorded as 30.32% and for the year was 109.37%, while the YTD performance remained at 20.15%. CGNX has Average True Range for 14 days of 1.88.
Aetna Inc. (NYSE:AET) [Trend Analysis] retains strong position in active trade, as shares scoring -3.26% to $125.27 in active trade session, while looking at the shares volume, around 4.21 Million shares have changed hands in this session. Khang&Khang LLP reported that filing of a class action lawsuit against Aetna Inc. (AET) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired shares between August 15, 2016 and January 20, 2017 inclusive, are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff motion deadline.
The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: Aetna and its senior executives attempted to sway Aetna’s engagement in the Public Exchanges for positive treatment from regulators in regards to the Humana acquisition; that the Company threatened to rescind its participation in public health insurance exchanges if the Department of Justice attempted to block the merger; that Aetna withdraw from some public health insurance exchanges, as per its threat of leaving the marketplace once the DOJ filed suit to improve its litigation; that Aetna withdrew from public health insurance exchanges that were profitable for Aetna; and that as a result, Defendants’ statements regarding Aetna’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. The firm has institutional ownership of 92.50%, while insider ownership included 0.20%. AET attains analyst recommendation of 2.20 with week’s performance of 2.94%. Investors looking further ahead will note that the Price to next year’s EPS is 11.06%.